Popular Trials
Mineral
Selenium for Colorectal Cancer
Selenium's ability to prevent colorectal cancer (CRC) has been suspected for nearly 30 years, but has never been directly studied in humans. The investigators will directly assess selenium's ability to prevent CRC by measuring alterations in aberrant crypt foci (ACF), an accepted surrogate marker for CRC. ACF's are very small (i.e., microscopic) collections of abnormally shaped cells that are a commonly used marker of CRC risk. Screening colonoscopy at UIC routinely uses methods that allow ACF counting to be done as a part of standard practice. ACF's are not fixed, like polyps or cancers, but can disappear as a person's risk for developing CRC decreases. The investigators propose giving patient's with 6 or more ACF's 200 mcg selenized yeast or placebo, and determining if there is a drug-dependant decrease in ACF number. The primary objective is to determine whether selenized yeast supplementation, compared to placebo, causes significant reduction of ACF number from baseline levels. The primary endpoint will be change in ACF number
Behavioral Intervention
Physical Activity and Education for Colorectal Cancer
This trial is studying a physical activity program given together with health education materials to see how well it works compared with giving health education materials alone for patients who have undergone treatment for high-risk stage II or stage III colon cancer.
Behavioural Intervention
Garden-fresh produce and exercise for This is not a medical term.
The investigators propose a church-based health promotion program designed to reduce colon cancer risk in a mostly African American community served by the Lincoln Memorial Church in South Los Angeles. The investigators propose involving 20 overweight/obese community members in a 10-session health promotion program featuring weekly cooking classes, didactic nutrition instruction and brief bouts of exercise. Behavioral aim is to increase participants' fiber intake from commonly consumed plant foods and reduce their intake of pro-inflammatory foods. They will be followed for 3 months from time of enrollment. Intervention is expected to increase participants' mean stool weight and improve their Bristol Stool Chart score. Intervention is expected to reduce waist circumference and systolic blood pressure of participants. These effects are expected to be accompanied by self-reports of increased fiber intake and reduced intake of saturated fat and refined sugar as well as evidence of increased physical activity.
Popular Filters
Trials for Colorectal Cancer Patients
PD-1 Inhibitor
Dostarlimab for Colon Cancer
This trial is testing dostarlimab, a drug that helps the immune system fight cancer. It targets patients with a specific type of colon cancer that has certain genetic features and can be surgically removed. Dostarlimab works by helping the immune system recognize and destroy cancer cells.
Behavioural Intervention
ESTIMATE Training for Polyp Classification
This trial will teach trainees to estimate size of polyps in GI (Gastroenterology) using a video module + feedback. Outcome measures include accuracy of size and confidence level in classifying polyps.
CDK4/6 Inhibitor
Palbociclib + Cetuximab for Colon Cancer
This trial is testing a combination of two drugs, cetuximab and palbociclib, to treat patients with advanced colon cancer. The drugs work together to block cancer cell growth and division. The study focuses on patients whose cancer has specific protein characteristics and who have either not been treated with similar drugs before or have developed resistance after initial treatment.
Trials for Rectal Cancer Patients
Behavioural Intervention
ESTIMATE Training for Polyp Classification
This trial will teach trainees to estimate size of polyps in GI (Gastroenterology) using a video module + feedback. Outcome measures include accuracy of size and confidence level in classifying polyps.
Trials for Metastatic Patients
CDK4/6 Inhibitor
Palbociclib + Cetuximab for Colon Cancer
This trial is testing a combination of two drugs, cetuximab and palbociclib, to treat patients with advanced colon cancer. The drugs work together to block cancer cell growth and division. The study focuses on patients whose cancer has specific protein characteristics and who have either not been treated with similar drugs before or have developed resistance after initial treatment.
Chemotherapy +/− Surgery + Mitomycin C for Colorectal Cancer
This trial is testing whether using a warmed-up chemotherapy drug called mitomycin C after surgery can help kill leftover cancer cells in patients with advanced colon cancer that has spread to the abdomen. The goal is to see if this approach improves survival and quality of life. Mitomycin C has historically been used in the treatment of intraperitoneal carcinomatosis from colon cancer.
Anti-metabolites
Chemotherapy +/− Celecoxib for Colorectal Cancer
This trial is studying oxaliplatin, leucovorin calcium, and fluorouracil given together with or without celecoxib in treating patients with stage III colon cancer previously treated with surgery.
Chemotherapy
Chemotherapy + Atezolizumab for Colon Cancer
This trial is testing whether adding atezolizumab to standard chemotherapy works better than chemotherapy alone for patients with stage III colon cancer who have a specific genetic defect. The chemotherapy drugs aim to kill cancer cells, while atezolizumab helps the immune system attack the cancer. Researchers hope this combination will improve survival rates and quality of life for these patients.
Trials for MSS Positive Patients
Cancer Vaccine
ATP128 + VSV-GP128 + BI 754091 for Colorectal Cancer
This trial is assessing the safety and tolerability of the ATP128 vaccine when given alone or in combination with BI 754091. The trial will also assess the efficacy of the combination of ATP128 and VSV-GP128 when given in combination with BI 754091 in patients with microsatellite stable colorectal cancer.
Monoclonal Antibodies
Encorafenib + Cetuximab + Nivolumab for Colorectal Cancer
This trial is testing a combination of drugs to treat patients with colorectal cancer that has spread and cannot be removed by surgery. The drugs work by blocking enzymes needed for cell growth and by helping the body's immune system attack the cancer.
Tyrosine Kinase Inhibitor
Regorafenib + Immunotherapy for Colorectal Cancer
This trial is studying regorafenib in combination with ipilimumab and nivolumab to see if it can help to treat patients with colorectal cancer that has spread and is resistant to chemotherapy.
Trials for DMMR Positive Patients
PD-1 Inhibitor
Dostarlimab for Colon Cancer
This trial is testing dostarlimab, a drug that helps the immune system fight cancer. It targets patients with a specific type of colon cancer that has certain genetic features and can be surgically removed. Dostarlimab works by helping the immune system recognize and destroy cancer cells.
Chemotherapy
Chemotherapy + Atezolizumab for Colon Cancer
This trial is testing whether adding atezolizumab to standard chemotherapy works better than chemotherapy alone for patients with stage III colon cancer who have a specific genetic defect. The chemotherapy drugs aim to kill cancer cells, while atezolizumab helps the immune system attack the cancer. Researchers hope this combination will improve survival rates and quality of life for these patients.
PD-1 Inhibitor
Dostarlimab for Colon Cancer
This trial is testing the immunotherapy drug dostarlimab in patients with Stage II and III colon cancer. The goal is to see if the drug can shrink the tumors enough to avoid surgery. Dostarlimab helps the immune system attack the cancer cells.
Phase 3 Trials
PD-1 Inhibitor
Dostarlimab for Colon Cancer
This trial is testing dostarlimab, a drug that helps the immune system fight cancer. It targets patients with a specific type of colon cancer that has certain genetic features and can be surgically removed. Dostarlimab works by helping the immune system recognize and destroy cancer cells.
Chemotherapy +/− Surgery + Mitomycin C for Colorectal Cancer
This trial is testing whether using a warmed-up chemotherapy drug called mitomycin C after surgery can help kill leftover cancer cells in patients with advanced colon cancer that has spread to the abdomen. The goal is to see if this approach improves survival and quality of life. Mitomycin C has historically been used in the treatment of intraperitoneal carcinomatosis from colon cancer.
Anti-metabolites
Chemotherapy +/− Celecoxib for Colorectal Cancer
This trial is studying oxaliplatin, leucovorin calcium, and fluorouracil given together with or without celecoxib in treating patients with stage III colon cancer previously treated with surgery.
Trials With No Placebo
PD-1 Inhibitor
Dostarlimab for Colon Cancer
This trial is testing dostarlimab, a drug that helps the immune system fight cancer. It targets patients with a specific type of colon cancer that has certain genetic features and can be surgically removed. Dostarlimab works by helping the immune system recognize and destroy cancer cells.
Behavioural Intervention
ESTIMATE Training for Polyp Classification
This trial will teach trainees to estimate size of polyps in GI (Gastroenterology) using a video module + feedback. Outcome measures include accuracy of size and confidence level in classifying polyps.
CDK4/6 Inhibitor
Palbociclib + Cetuximab for Colon Cancer
This trial is testing a combination of two drugs, cetuximab and palbociclib, to treat patients with advanced colon cancer. The drugs work together to block cancer cell growth and division. The study focuses on patients whose cancer has specific protein characteristics and who have either not been treated with similar drugs before or have developed resistance after initial treatment.
View More Related Trials
Frequently Asked Questions
Introduction to colon cancer
What are the top hospitals conducting colon cancer research?
In the fight against colon cancer, several hospitals have emerged as leaders in conducting clinical trials that aim to improve treatment and outcomes for patients. One such institution is Alta Bates Summit Medical Center-Herrick Campus located in Berkeley, California. With four active colon cancer trials currently underway and a total of six completed studies dedicated to this condition, the hospital has been actively involved in research since recording its first trial in 2005. Similarly, Contra Costa Regional Medical Center in Martinez has also made significant contributions with four ongoing colon cancer trials and a notable history of eleven previously conducted studies dating back to their initial trial in 2004.
Moving further south to Modesto, Memorial Medical Center continues to play an important role with four active clinical trials focused on colon cancer and eight successful previous investigations since their inaugural study commenced in 2004. Likewise, Palo Alto Medical Foundation-Camino Division situated in Mountain View has established itself as another key player by conducting four ongoing colon cancer trials alongside seven accomplished ones that date back seventeen years ago when they initiated their groundbreaking investigation on this condition.
Notably contributing towards advancements within the field is Sutter Roseville Medical Center positioned at Roseville; In addition holding up through it's current participation within same number of concurrent examinations are eight earlier inquiries revolving around Colon Cancer which stretches out from past seventeen years commencing initially during year 2004.Its lasting presence atop these statistics proves how diligently each facility works toward understanding and combating this disease - ultimately leading us closer to better treatments for those affected by colon cancer.
These hospitals serve as beacons of hope for individuals facing colon cancer diagnosis across various locations while reflecting how medical professionals work tirelessly toward improving patient care through scientific exploration
Which are the best cities for colon cancer clinical trials?
When it comes to clinical trials for colon cancer, several cities emerge as top contenders. Denver, Colorado leads with 19 active trials focusing on treatments like celecoxib, Fluorouracil, and Atezolizumab. Los Angeles, California follows closely with 16 ongoing studies examining interventions such as Atezolizumab and celecoxib. Anchorage, Alaska also shows promise with 15 active trials investigating treatment options including Subprotocol C2 (MET exon 14 deletion/mutation), celecoxib, and Fluorouracil. These cities offer individuals battling colon cancer access to cutting-edge research that may pave the way for improved outcomes in their fight against the disease.
Which are the top treatments for colon cancer being explored in clinical trials?
Colon cancer research is constantly evolving, and in recent clinical trials, two treatments have emerged as promising contenders. Dostarlimab has shown potential with one active trial dedicated to colon cancer. It joined the scene in 2023 and has already accumulated a total of two clinical trials for this specific type of cancer. Another intriguing approach being explored is aerobic exercise, which also boasts one active trial and two all-time colon cancer trials since its first listing in 2023. These innovative treatments offer hope for improved outcomes in fighting this formidable disease by combining medical advancements with lifestyle interventions.
What are the most recent clinical trials for colon cancer?
Exciting advancements are being made in the field of colon cancer research through recent clinical trials. One notable trial focuses on neoadjuvant therapy, which aims to improve treatment outcomes by administering therapies before surgery. Another study is evaluating the efficacy of dostarlimab, a potential breakthrough immunotherapy option for colon cancer patients. Additionally, two different arms of a trial are investigating the effectiveness of encorafenib and cetuximab combination therapy as well as fentanyl citrate and propofol anesthesia in colon cancer treatment. By exploring these innovative approaches, researchers hope to enhance therapeutic options and provide better outcomes for individuals battling colon cancer.
What colon cancer clinical trials were recently completed?
Recently, several clinical trials investigating treatments for colon cancer have reached completion, reflecting the relentless efforts of researchers in this field. In January 2022, Mayo Clinic successfully concluded a trial examining the Colorectal cancer Peptide Vaccine PolyPEPI1018. Mirati Therapeutics Inc.'s investigation into MRTX849 also wrapped up in August 2021. While George E. Peoples' PalloV-CC study reached its conclusion in July 2019, Mayo Clinic's examination of American Ginseng completed in March 2019 and Asha Nayak's pembrolizumab trial finalized in January 2018. Furthermore, both Academic and Community Cancer Research United and Wake Forest University Health Sciences conducted studies that ended earlier; the former's Pharmacological Study was completed in March 2015 while the latter's exploration of 6,8-bis(benzylthio)octanoic acid finished their research project in January 2015.